Kabra Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 271637,
    "name": "Kabra Drugs",
    "stock_name": "Kabra Drugs",
    "full_name": "Kabra Drugs Ltd",
    "name_url": "stocks-analysis/kabra-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "30.00",
    "chg": 0.9,
    "chgp": "3.09%",
    "dir": 1,
    "prev_price": "29.10",
    "mcapval": "72.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524322,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE323K01017",
    "curr_date": "Dec 24",
    "curr_time": "",
    "bse_nse_vol": "5.06 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 24, 2025",
    "traded_date_str": "2025 12 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kabra-drugs-271637-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3703266",
        "imagepath": "",
        "date": "2025-11-14 23:52:54",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ..."
      },
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3699169",
        "imagepath": "",
        "date": "2025-11-13 23:25:50",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s..."
      },
      {
        "title": "When is the next results date for Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-kabra-drugs-3681427",
        "imagepath": "",
        "date": "2025-11-07 23:22:02",
        "description": "The next results date for Kabra Drugs is scheduled for 13 November 2025...."
      }
    ],
    "total": 52,
    "sid": "271637",
    "stock_news_url": "https://www.marketsmojo.com/news/kabra-drugs-271637"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "22-Dec-2025",
      "details": "Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/01/2026 inter alia to consider and approve Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of the Board of Directors of is scheduled to be held on Thursday 1 January 2026 at the Corporate office at Chennai of the Company",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Dec-2025",
      "details": "Newspaper Advertisement for Notice of Extra-Ordinary General Meeting & E-voting.",
      "source": "BSE"
    },
    {
      "caption": "Submission Of Notice Of Extra Ordinary General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015",
      "datetime": "03-Dec-2025",
      "details": "Notice of Extra Ordinary General Meeting held on 26th December 2025 at Friday.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "01 Jan 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Kabra Drugs?

2025-11-14 23:52:54

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ...

How has been the historical performance of Kabra Drugs?

2025-11-13 23:25:50

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s...

When is the next results date for Kabra Drugs?

2025-11-07 23:22:02

The next results date for Kabra Drugs is scheduled for 13 November 2025....

View All News